Search

Search Constraints

You searched for: Author/Creator Egawa, Shin

Search Results

21. Differences in sex hormone recovery profile after cessation of 12‐week gonadotropin‐releasing hormone antagonist versus agonist therapy. (24th September 2021)

22. Differential expression of androgen receptor variants in hormone‐sensitive prostate cancer xenografts, castration‐resistant sublines, and patient specimens according to the treatment sequence. Issue 9 (18th April 2019)

23. Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. Issue 5 (May 2021)

24. Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?. (25th July 2016)

25. Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?. (13th May 2022)

26. Does castration status affect docetaxel‐related adverse events? :Identification of risk factors for docetaxel‐related adverse events in metastatic prostate cancer. Issue 14 (29th June 2022)

28. Earlier use of androgen receptor‐axis‐targeted drugs may improve overall survival in patients with non‐metastatic castration‐resistant prostate cancer. Issue 10 (10th April 2018)

29. Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective study. Issue 13 (23rd June 2022)

30. Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. Issue 1 (17th January 2022)